TABLE 2.

STEC prevalence in human clinical stool samples

YearMethodology used for detection and isolation of STECbNo. of stool samples (coprocultives)
Total no. analyzedNo. (%) STEC positiveb with:
STEC detectedO157:H7 isolatedNon-O157 isolated
1992For O157:H7, SMAC + Vero/HeLa cells;1860 (0)0 (0)0 (0)
1993for non-O157, MAC + Vero/HeLa cells4394 (0.9)0 (0)4 (0.9)
19945107 (1.4)0 (0)7 (1.4)
1995For O157:H7,70710 (1.4)3 (0.4)7 (1.0)
1996BPWvcc+IMS+CTSMAC+6849 (1.3)1 (0.1)8 (1.2)
1997SMAC+PCR-stx1-stx2-eae-γ1;85026 (3.0)7 (0.8)17 (2.0)
1998for non-O157,1,04842 (4.0)4 (0.4)27 (2.6)
1999MAC+CTSMAC+PCR-stx1-stx263028 (4.4)9 (1.4)17 (2.7)
Total5,054126 (2.5)24 (0.5)87 (1.7)
  • a IMS, immunomagnetic separation; PCR-stx1-stx2-eae-γ1, PCR with primers specific for stx1, stx2, and eae-γ1; PCR-stx1-stx2, PCR with primers specific for stx1 and stx2.

  • b STEC O157:H7 and STEC non-O157 strains were isolated in two samples.